Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DOVIPA: Dostarlimab and Vitamin D3 with mFOLFIRINOX in Metastatic Pancreatic Cancer
NCT06757244Phase 2Recruiting
- Sponsor
- Hôpital Foch
- Start
- Feb 2025
- Primary completion
- Feb 2028
- Modality
- Immune Checkpoint Inhibitors, Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
A Phase 2 trial of dostarlimab, vitamin d in pancreatic adenocarcinoma (PDAC), sponsored by Hôpital Foch. Started Feb 2025; status: recruiting.
02
Drugs
dostarlimabvitamin d
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT06757244.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06757244.